We claim

1. A composition, comprising particles comprising at least 95% by weight of sorafenib, or a pharmaceutically acceptable salt thereof, wherein the particles have a specific surface area (SSA) of at least 2 m^2/g and have a mean particle size by volume distribution of between about 0.7 μm and about 8μm.

2. The composition of claim 1, wherein the particles have a SSA of at least 5 m^2/g.

3. The composition of claim 1, wherein the particles have a SSA of at least 10 m^2/g.

4. The composition of any one of claims 1-3, wherein the particles have a SSA of between 2m^2/g and about 50 m^2/g, between about 3 m^2/g and 50 m^2/g, between5m^2/g and 50 m^2/g, between 7m^2/g and 50 m^2/g, or between 10 m^2/g and 50 m^2/g.

5. The composition of any one of claims 1-4, wherein the particles have a mean particle size by volume distribution of between about 1 μm and about 8 μm.

6. The composition of any one of claims 1-5, wherein the particles comprise at least 96%, 97%, 98%, 99%, or 100% of sorafenib, or a pharmaceutically acceptable salt thereof.

7. The composition of any one of claims 1-6, wherein the particles are uncoated and exclude polymer, protein, polyethoxylated castor oil and polyethylene glycol glycerides composed of mono-, di- and triglycerides and mono- and diesters of polyethylene glycol.

8. The composition of any one of claims 1-7, wherein the composition comprises a suspension further comprising a pharmaceutically acceptable liquid carrier.

9. The composition of any one of claims 1-8, further comprising one or more components selected from the group consisting of polysorbate, methylcellulose, polyvinylpyrrolidone, mannitol, and hydroxypropyl methylcellulose.

10. The composition of any one of claims 1-9, wherein, the particles have a mean bulk density between

(a) about 0.010 g/cm^3 and about 0.200 g/cm^3, between about 0.025 g/cm^3 and about 0.175 g/cm^3, between about 0.050 g/cm^3 and about 0.150 g/cm^3, between about between about 0.075 g/cm^3 and about 0.125 g/cm^3, or between about 0.085 g/cm^3 and about 0.115 g/cm^3, tapped;

(b) between about 0.010 g/cm^3 and about 0.200 g/cm^3, between about 0.020 g/cm^3 and about 0.175 g/cm^3, between about 0.040 g/cm^3 and about 0.125 g/cm^3, between about between about 0.050 g/cm^3 and about 0.100 g/cm^3, or between about 0.060 g/cm^3 and about 0.090 g/cm^3, not tapped;

(c) less than about 0.200 g/cm^3, 0.175 g/cm^3, 0.150 g/cm^3, or 0.125 g/cm^3, tapped; and/or

(d) less than about 0.200 g/cm^3, 0.175 g/cm^3, 0.150 g/cm^3, or 0.125 g/cm^3, 0.100 g/cm^3, or 0.090 g/cm^3, not tapped.

11. The composition of any one of claims 1-10, wherein the pharmaceutically acceptable salt of sorafenib comprises sorafenib tosylate.

12. A method for treating a tumor, comprising administering to a subject with a tumor an amount effective to treat the tumor of the composition of any one of claims 1-11.

13. The method of 12, wherein the tumor is selected from the group consisting of thyroid carcinomas, renal cell carcinomas, hepatocellular carcinomas, pancreatic tumors, prostate tumors, bladder tumors, lung tumors and ovarian carcinomas.

14. The method of 12 or 13, wherein the subject is a human subject.

15. The method of any one of claims 12-14, wherein the composition is administered by intra-tumoral injection, peri-tumoral injection, or intra-peritoneal injection.

16. A method for making sorafenib particles, comprising:

(a) introducing (i) a solution comprising at least one solvent, and at least one solute comprising sorafenib or a pharmaceutically acceptable salt thereof into a nozzle inlet, and (ii) a compressed fluid into an inlet of a vessel defining a pressurizable chamber;

(b) passing the solution out of a nozzle orifice and into the pressurizable chamber to produce an output stream of atomized droplets, wherein the nozzle orifice is located between 2 mm and 20 mm from a sonic energy source located within the output stream, wherein the sonic energy source produces sonic energy with an amplitude between 10% and 100% during the passing, and wherein the nozzle orifice has a diameter of between 20 μm and 125 μm;

(c) contacting the atomized droplets with the compressed fluid, to cause depletion of the solvent from the atomized droplets, to produce compound particles comprising at least 95% sorafenib or a pharmaceutically acceptable salt thereof, wherein the particles have a specific surface area (SSA) of at least 2 m^2/g and have a mean particle size by volume distribution of between about 0.7 μm and about 8μm,

wherein steps (a), (b), and (c) are carried out under supercritical temperature and pressure for the compressed fluid.

17. The method of claim 16, further comprising:

(d) contacting the compound particles produced in step (c) with an anti-solvent to cause further depletion of the solvent from the compound particles, wherein step (d) is carried out under supercritical temperature and pressure for the anti-solvent.

18. The method of any one of claims 16-17, wherein a flow rate of the solution through the nozzle has a range from about 0.5 mL/min to about 30 mL/min.

19. The method of any one of claims 16-18, wherein the sonic energy source comprises one of a sonic horn, a sonic probe, or a sonic plate.

20. The method of any one of claims 16-19, wherein the sonic energy source has a frequency between about 18 kHz and about 22 kHz, or about 20 kHz.

21. The method of any one of claims 16-20, further comprising:

(e) receiving the plurality of particles through the outlet of the pressurizable chamber; and

(f) collecting the plurality of particles in a collection device.

22. The method of any one of claims 16-21, wherein the compressed fluid is super critical carbon dioxide.

23. The method of any one of claims 17-22, wherein the anti-solvent is super critical carbon dioxide.

24. The method of any one of claims 16-23, wherein the solvent may include, but is not limited to acetone, ethanol, methanol, or combinations thereof.

25. The method of any one of claims 16-24, wherein the solvent comprises acetone.

26. The method of any one of claims 16-25, wherein the method is carried out between 31.1°C to about 60°C, and at between about 1071 psi and about 1800 psi.

27. The method of any one of claims 16-26, wherein the particles have an SSA of at least 5 m^2/g, at least 7.5 m^2/g, or at least 10 m^2/g, and/or wherein the particles are the particles of any one of claims 1-11.

28. Compound particles prepared by the method of any one of claims 16-27.